阿裏健康(00241.HK)建罕見病全球藥物信息平臺 首批上線22款創新藥
阿裏健康(00241.HK)與博鰲樂城罕見病臨牀醫學中心宣佈合作建設罕見病全球藥物信息平臺 ,雙方擬通過搭建線上線下一體化的健康服務平臺,解決罕見病患者使用境外創新治療藥物的困難。
平臺首批上線22款創新罕見病藥品,包括苯丁酸甘油酯、阿米(口比)啶、阿法諾(月太)等國內暫無的藥品,用戶只需在支付寶首頁搜索「患者援助」進入罕見病藥品專區,按要求成功提交基礎信息後,即可使用相關服務。
阿裏健康資深副總裁馬立指出,信息不對稱是目前醫療行業面臨的痛點,罕見病由於發病率低、症狀複雜、診斷困難,導致難以快速獲得藥品相關信息,希望通過互聯網技術打通罕見病就醫及用藥環節,幫助患者接受更好的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.